Savara Inc. (SVRA): The $11 Analyst Target and Path to +120% Upside

Key Takeaways

• The central $11 stock price target is the arithmetic mean of the verified analyst price targets reviewed, rounded from a calculated average of roughly $11.06–$11.17.
• Analyst targets range widely, from a low of $9 to a high of $16, reflecting genuine disagreement about Savara's commercial ramp.
• With Savara Inc. (SVRA) trading near $4.99, reaching $11 would require a gain of roughly 120%—a very large move.
• The strongest support is the upcoming PDUFA decision date of November 22, 2026 for MOLBREEVI (molgramostim), its lead therapy for autoimmune pulmonary alveolar proteinosis (aPAP).
• The biggest risks are binary regulatory outcomes, a pre-revenue business model, ongoing cash burn, and potential shareholder dilution.
• Analyst views skew strongly bullish—nearly all covering firms rate the stock Buy—but the wide $9–$16 spread shows no consensus on valuation.
• You can explore more details on Major News, Today's Price Move, the Forecast, and upcoming Earnings on Tickeron's dedicated pages.
• For AI-driven market monitoring, explore Tickeron's Trending AI Robots.

Analyst Price Targets and Consensus View

Savara is covered by roughly eight to nine sell-side analysts, and the targets reviewed cluster between $9 and $16. On the cautious end, Wells Fargo carries a $9 target, while Piper Sandler's Yasmeen Rahimi holds the Street-high $16 target. In between, H.C. Wainwright is at $10, Jefferies' Andrew Tsai at $10.50, Guggenheim at $11, and both JPMorgan and Citigroup initiated coverage in October 2026 with $12 targets. The arithmetic mean of these verified targets lands near $11.06–$11.17, which rounds to the $11 central target used here. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

The dispersion is meaningful. Lower targets reflect a conservative view of launch execution and peak-sales penetration, while the $16 target assumes a faster, larger commercial ramp and greater ex-U.S. upside. Crucially, the mean is a statistical midpoint, not a promise, and the gap between $9 and $16 underscores how much of the valuation debate hinges on one binary event: FDA approval.

Current Market Position and Path Toward the Target

Shares traded near $4.99 in mid-November 2026, within a 52-week range that has stretched from roughly $4 to above $7. Reaching $11 would require a gain of about 120%, which qualifies as a very large move for any established company and is especially demanding for a pre-revenue biotech.

The path runs directly through the November 22, 2026 PDUFA (Prescription Drug User Fee Act) decision date for MOLBREEVI. Savara's BLA (Biologics License Application) was accepted under Priority Review, and the FDA extended the original August 2026 date by three months without citing safety, efficacy, or manufacturing concerns. A positive decision would shift the market's focus from regulatory risk to commercial launch, potentially re-rating the stock toward the higher end of the target range. A negative or delayed outcome could pressure shares sharply in the opposite direction.

What Could Support a Move Toward the Target

• Regulatory catalysts: MOLBREEVI holds Breakthrough Therapy, Fast Track, and Orphan Drug designations, and applications are also under review with the EMA and UK MHRA.
• Unmet need: aPAP has no approved therapy, and positive Phase 3 IMPALA-2 data support the efficacy case.
• Balance sheet: Savara reported about $173 million in cash and short-term investments as of June 30, 2026, plus access to up to roughly $150 million in non-dilutive capital upon FDA approval.
• Valuation headroom: Jefferies models roughly $500 million in U.S. peak sales and a first-twelve-months consensus sales range of $70–80 million, implying substantial upside if launch execution matches expectations.

What Could Prevent the Target From Being Reached

• Binary regulatory risk: an FDA complete response letter or further delay would likely derail the timeline underpinning most targets.
• No revenue yet: Savara reported a second-quarter 2026 net loss of about $40.2 million, or $(0.16) per share, and remains dependent on external financing.
• Dilution: an expanded share authorization increases the potential for future equity raises that could dilute existing holders.
• Commercial uncertainty: launch pricing, reimbursement, and patient identification all carry execution risk that analysts weigh differently, contributing to the wide target range.

Technical Levels and Market Structure

The stock has been volatile around the regulatory catalyst. It recently recovered from the low-$4.20s in late October 2026 to the mid-$4.80s, but remains well below its 52-week high near $7. That prior high zone acts as meaningful overhead resistance on any path toward double digits, while the $4 area has functioned as durable support. The $11 target sits far above both the recent trading range and the prior peak, meaning the stock would need to break out decisively to make a technical case for that level.

Time Horizon and What Investors Should Monitor

Analyst price targets generally reflect a research horizon of about 12 months, though individual firms vary. For Savara, the near-term calendar is unusually event-driven. The November 22, 2026 PDUFA decision is the dominant catalyst, followed by EMA and MHRA decisions expected in Q1 2027 and Q4 2026, respectively. Investors should also watch quarterly cash burn, any capital-raising announcements, launch preparation updates, and analyst target revisions after the FDA ruling.

Using Tickeron’s AI Daily Buy/Sell Signals for Monitoring

In my view, tools like Tickeron’s AI Daily Buy/Sell Signals can provide a useful layer of insight when tracking event-driven names. I’m watching this closely because the signals help flag shifts in momentum without needing to review every chart manually. From what I see, this approach keeps the focus on data-driven observations around key dates like the upcoming PDUFA.

Final Assessment

The $11 central target is the arithmetic mean of verified analyst targets spanning $9 to $16, and it sits roughly 120% above the current price—a very large, catalyst-dependent move. The case for reaching it rests almost entirely on a favorable FDA decision and a credible commercial launch, supported by a solid cash position and genuine unmet medical need. The case against it rests on binary regulatory risk, continued losses, dilution, and the possibility that launch economics disappoint even if approval arrives. Given the wide analyst range and the concentrated event risk around November 22, 2026, the $11 figure is best understood as a midpoint of sharply diverging views rather than a forecast.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Contributor

Sergey Savastiouk|Expert

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.

Notable companies

Industry description

Market Cap

High and low price notable news

Volume